Abstract

This study explains the engineering of polylactide-polyethylene succinate glycol nanomaterials (NMs), to achieve superior anticancer effectiveness in prostate cancer therapy as a carriers of crizotinib (CZT) and marizomib (MAR). We have shown that the block polymers and hydrophobic drugs can be self-assembled to construct a highly stable nanocarrier with highly adaptable to support the use of cancer medicines. The Drug Release analysis revealed that the interference in the hydrophobic cores of micelles was a continuous release series. In both PC3pip and LNCAP prostate cancer cells, CZT@MAR NMs demonstrated noticeable cytotoxic effects in a dose-responsive method. In addition, morphology analysis and the AO-EB and nuclear staining assay showed a higher effectiveness in prostate cancer for nanomaterials. The polymeric nanomaterials displayed a prominent existence in the cytoplasmic cell regions, which shows a characteristic cell uptake by endocytosis. A significant apoptosis, compared to free CZT@MAR apoptosis, was found in the FITC-Annexin V/PI staining-based apoptosis analysis. In this juncture, the alternative drug delivery mechanism for the improvement of CZT@MAR chemotherapeutic effectiveness in prostate cancer chemotherapy modification PLA nanoparticles.

摘要

本研究解释了聚丙交酯-聚丁二酸乙二醇酯纳米材料 (NMs) 的工程设计，作为克唑替尼 (CZT) 和马里佐米 (MAR) 的载体，在前列腺癌治疗中实现了卓越的抗癌效果。我们已经证明，嵌段聚合物和疏水性药物可以自组装以构建高度稳定的纳米载体，具有高度的适应性，以支持癌症药物的使用。药物释放分析表明，对胶束疏水核的干扰是一个连续的释放序列。在 PC3pip 和 LNCAP 前列腺癌细胞中，CZT@MAR NMs 在剂量响应方法中表现出明显的细胞毒性作用。此外，形态分析和 AO-EB 和核染色试验表明纳米材料在前列腺癌中具有更高的有效性。聚合物纳米材料在细胞质细胞区域中表现出突出的存在，这显示出通过内吞作用进行的特征性细胞摄取。在基于 FITC-Annexin V/PI 染色的细胞凋亡分析中发现与游离 CZT@MAR 细胞凋亡相比显着的细胞凋亡。在这个时刻，用于提高 CZT@MAR 化疗效果的替代药物递送机制在前列腺癌化疗修饰 PLA 纳米粒子中。